Skip to main content

Advertisement

SpringerLink
Log in

Elevated serum level of interleukin-32α in the patients with myasthenia gravis

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

A new cytokine, interleukin-32 (IL-32), has been implicated in the pro-inflammatory immune responses in several autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel diseases. Myasthenia gravis (MG) is a well-characterized autoimmune disease directed at the postsynaptic acetylcholine receptor (AChR) or end plate of the neuromuscular junction. IL-32 is a cytokine that induces tumor necrosis factor (TNF)-α, IL-6, IL-1β, and chemokine. IL-6, TNF-α, and IL-2 are related to the pathogenesis and immunoregulation of MG. The gene expression of IL-32 is increased in human natural killer (NK) cells and T lymphocytes when stimulated by IL-2 or mitogen. NK cells influence the development of experimental autoimmune MG (EAMG) and possibly MG. The aim of this study was to examine whether IL-32α levels are increased in patients with MG and to investigate the relationship between IL-32α levels and disease activity in human MG. Serum IL-32α levels were significantly higher in the MG patients (p = 0.03): 460.07 ± 192.30 pg/mL in MG patients and 248.45 ± 188.42 pg/mL in the healthy control group. Although there was no significant statistical difference, serum IL-32α levels of patients with both anti-AChR binding and blocking antibodies trended to be higher than those without either antibodies (521.56 ± 212.92 pg/mL vs. 339.52 ± 182.78 pg/mL, p = 0.16). IL-32α serum levels tended to decrease with clinical improvement in generalized MG. This study suggests the possibility that IL-32 might contribute to MG pathogenesis or immunoregulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG (2000) Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 1:245–251

    Article  PubMed  CAS  Google Scholar 

  2. Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present and future. J Clin Invest 116:2843–2854

    Article  PubMed  CAS  Google Scholar 

  3. Dahl CA, Schall RP, He HL, Cairns JS (1992) Identification of a novel gene expressed inactivated natural killer cells and T cells. J Immunol 148:597–603

    PubMed  CAS  Google Scholar 

  4. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA (2005) Interleukin-32: a cytokine and inducer of TNF alpha. Immunity 22:131–142

    PubMed  CAS  Google Scholar 

  5. Dinarello CA, Kim SH (2006) IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65(Suppl 3):iii61–iii64

    Article  PubMed  Google Scholar 

  6. Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH, Dinarello CA (2008) Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 181:557–565

    PubMed  CAS  Google Scholar 

  7. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB (2006) IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 103:3298–3303

    Article  PubMed  CAS  Google Scholar 

  8. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A (2007) Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 149:480–486

    Article  PubMed  CAS  Google Scholar 

  9. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23

    PubMed  Google Scholar 

  10. Drachman DB (1994) Myasthenia gravis. N Engl J Med 330:1797–1810

    Article  PubMed  CAS  Google Scholar 

  11. Conti P, Youinou P, Theoharides TC (2007) Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev 6:131–137

    Article  PubMed  CAS  Google Scholar 

  12. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, Kim SH (2005) IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 102:16309–16314

    Article  PubMed  CAS  Google Scholar 

  13. Jander S, Stoll G (2002) Increased serum levels of the interferon-gamma-inducing cytokine interleukin-18 in myasthenia gravis. Neurology 59:287–289

    PubMed  Google Scholar 

  14. Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS, Adorini L (1999) Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 163:2403–2409

    PubMed  CAS  Google Scholar 

  15. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361

    Article  PubMed  CAS  Google Scholar 

  16. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135

    Article  PubMed  Google Scholar 

  17. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014–2022

    Article  PubMed  CAS  Google Scholar 

  18. Duan RS, Wang HB, Yang JS, Scallon B, Link H, Xiao BG (2002) Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun 19:169–174

    Article  PubMed  Google Scholar 

  19. Deng C, Goluszko E, Tüzün E, Yang H, Christadoss P (2002) Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol 169:1077–1083

    PubMed  CAS  Google Scholar 

  20. Jelinek DF, Lipsky PE (1987) Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. J Immunol 139:2970–2976

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurology, Gangnam Severance Hospital, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 146-92 Gangnam-gu, Seoul, 135-720, Republic of Korea

    Sang-Jun Na, Seon-Hwa So, Kee Ook Lee & Young-Chul Choi

  2. Department of Neurology, Konyang University College of Medicine, Daejeon, Republic of Korea

    Sang-Jun Na & Kee Ook Lee

Authors
  1. Sang-Jun Na
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seon-Hwa So
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kee Ook Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Young-Chul Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-Chul Choi.

Additional information

S.-J. Na and S.-H. So are joint first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Na, SJ., So, SH., Lee, K.O. et al. Elevated serum level of interleukin-32α in the patients with myasthenia gravis. J Neurol 258, 1865–1870 (2011). https://doi.org/10.1007/s00415-011-6036-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-011-6036-7

Keywords

Search

Navigation